

Original Article**Serologic response to hepatitis B vaccine in health care workers, Kermanshah, Iran**

A. Janbakhsh MD\*, B. Sayad MD\*, S. Vaziri MD\*, P. Aieni MD\*\*

**ABSTRACT**

**Background:** Hepatitis B is a major infectious risk factor for health-care workers (HCWs) and public- safety workers. Although seroconversion rate following hepatitis B vaccination is estimated to be more than 90%, serologic response to Heberbiovac HB vaccine currently given in our center in Kermanshah province has been varied in different experiences, So, this study was conducted to determine serologic response in HCWs.

**Methods:** In a descriptive-cross sectional study, in 138 HbcAb from 10 health care centers, HbcAb negatives and vaccinated with Heberbiovac HB (Cuba made, available vaccine in Iran), HbsAb titer was assessed by ELISA. Serologic response as antibody titer equal or more than 10mIU/ml considered protective level (serologic responder). The data were analyzed by SPSS software, using X<sup>2</sup> and Fisher exact test.

**Results:** Within 138 HCWs(60.1% female and 39.9% male), 69.6% had serologic response. The age had significant role in serologic response rate, but sex, weight, smoking and interval from the last time of vaccine reception were not effective factors.

**Conclusion:** Serologic response rate to HBV vaccine in Kermanshah was much lower than other experiences. We need more information about the efficacy of Heberbiovac HB in high-risk groups and general population, the reasons of low efficacy and increasing serologic response.

**Keywords:** Hepatitis B, Vaccine, Serologic response, Heberbiovac HB, Health-care workers

JRMS 2005; 10(3): 147-149

Hepatitis B is a major infectious risk factor for health-care workers (HCWs) and public population. Acute hepatitis B may lead to chronic carrier state in 6-10% of patients<sup>(1)</sup>. On the other hand, chronic infection may result in various degrees of inflammation or necrosis, leading to cirrhosis and hepatocellular carcinoma. Hepatitis D virus may also superimpose to HbsAg positive patients and increase life threatening complications<sup>2</sup>.

HCWs are at risk of HBV infection more than general population. Although serologic response to immunization is not complete, but vaccination can produces immunity in most vaccine recipients. Some factor such as sex, age, obesity, route of injection and smoking can influence seroconversion rate<sup>1, 3</sup>. In our country, all neonates, HCWs, medical students, accidentally exposed peoples and other high-risk groups have vaccinated routinely against hepatitis B, since 9 years ago. A few derivations of HBV vaccine are avail-

able in different countries (Recombivax HB, Engerix, Heptavax), but they are equally effective and approximately 90% of healthy adults will develop protective antibody<sup>4, 5, 6, 7</sup>. The only available vaccine in Iran is Heberbiovac HB and we aimed to know the efficacy of current vaccination program against HBV infection in high-risk groups and determine susceptibility rate in Kermanshah province, located in west site of Iran.

**Subjects and Methods**

In a descriptive cross-sectional study, 138 health-care workers were simply sampled from 10 health care centers of Kermanshah medical university. ELISA (RADIM kit) assessed the HbsAb titer. The antibody titer equal or more than 10mIU/ml considered protective level (serologic responder).

Our subjects had vaccinated with 3 doses of Heberbiovac HB (Cuba made), according to international protocol. They didn't have previous

\* Assistant Professor, Department of Infectious Disease, Sina Hospital, Kermanshah University of medical sciences, Kermanshah, Iran

\*\* Infectious Disease Specialist, Hamadan University of Medical Sciences, Hamadan, Iran.

Correspondence to: Dr Alireza Janbakhsh, Sina University Hospital, Kermanshah, Iran. E-mail: a-janeaphsh@yahoo.com

history of HBV infection and were HbcAb negative. Characteristics data such as sex, age, weight, smoking and interval from the last time of vaccine reception were obtained.

The data was analyzed by SPSS software using  $X^2$  and Fisher exact Tests.

## Results

No of the subjects had history of antibody response assessment after complete vaccination. Among 138 subjects (60.1% female and 39.9% male), the mean age was 36.94 years (range from 29 to 55). Responders and non-responders were

69.6% and 30.4% of subjects, respectively. Serologic response was detected in 74.7 % of females, 61.8% of males, and 61.7% of obese subjects and in 73.6% of thin or normal subjects, without significant difference. The response rate in subjects older than 40 years (58%) and in subjects younger than 40 years (76.1%) were significantly different ( $p < 0.05$ ). Serologic response in smokers and in nonsmokers has not significant difference. The frequency of last vaccination dose before or after 3 years was not statistically different. Detailed results have listed in Table 1.

**Table 1:** Demographic comparison of responders and non responders

Variables		Serologic Response		Statistical Correlation
		Responder	Non-Responder	
Sex	Male	34(61.8%)	21(48.2%)	NO
	Female	62(74.7%)	21(25.3%)	
Weight	Obese	27(61.7%)	20(38.3%)	NO
	Non obese	67(73.6%)	24(26.4%)	
Age	<40y	67(76.1%)	21(23.9%)	yes
	≥40y	29(58%)	21(42%)	
Smoking	Smoker	10(66.6%)	5(33.3%)	NO
	Non smoker	86(69.9%)	37(30.1%)	
Last Vaccination Dose	<3y	57(70.4)	24(29.6%)	NO
	≥3y	39(68.4%)	18(31.6%)	

## Discussion

Serologic response rate to HB vaccine was seen in 69.6 % (74.7% male, 61.8% female) of Kermanshah HCWs which is lower than other similar studies in Iran and over than yazd study that it was 58.8%<sup>4-7,9-12</sup>. It may be due to less effective Heberbiovac HB than other similar vaccines.

On the other hand, the frequency of last vaccination dose before or after 3 years in our study was not uniform for all subjects. So, the gradually decline of antibody level is possible and vaccinated people after 3 years (70.4%) had low antibody level, too. Technical problems such as vaccine storage condition, safe transfer chain and injection quality may affect serologic response, but these mentioned parameters could not be prominent in our experienced health care system.

We found that more than 30% of vaccinated HCWs may be sensitive to HBV infection, Al-

though symptomatic infection is rare in immunized peoples who developed protective levels of antibody even though then is eventual loss of detectable antibody in up to 50% of those peoples 5-10 years after immunization. For this reason, there is currently no recommendation for periodic boosting of HCWs who have responded to hepatitis B vaccine<sup>13</sup>

The assessment of HbsAb level 1-2 months after complete immunization and revaccination is suggested for HCWs and HIV infected and some high risk groups<sup>14,15</sup>, but this is not routinely performed in our vaccination program.

In this study, serologic response rate was not different between both sexes, although some previous studies confirmed it<sup>11, 12, 16, 17</sup> and another showed it more in female than male<sup>1, 9, 10</sup>.

Like other studies<sup>1,16,17</sup>, serologic response rate was significantly different in two age groups; higher in 40 years and younger, lower in older

than 40 years ( $p < 0.05$ ). Therefore, HCWs should be immunized before age 40, as soon as possible.

In our study, body weight, smoking and the time after last vaccine dose aren't effective factors on antibody level, although they were important related factors in some reports<sup>1,17</sup>.

We need more information about the efficacy

of Heberbiovac HB in high-risk groups and general population, the reasons of low efficacy and increasing serologic response, We recommend immunologic assessment on vaccinated HCWs 30 days after routine vaccination and modifying HBV immunization plan for non-responder subjects<sup>18</sup>.

## References

1. Robinson WS, *Hepatitis B virus and Hepatitis D virus in: Mandell, Douglas and Bennett's. Principles and practice of Infectious Disease, 5th ed. Churchill Livingstone, Philadelphia 2000: 1652-85.*
2. Malekzadeh R. *Viral Hepatitis in: Azizi, Hatami, Janghorbani. Epidemiology of communicable disease in Iran. 1th ed. Eshtiagh, Tehran 2000: 714-42.*
3. Wood RC, Francis DP, White KE, et al. *Risk factors for lack of detectable antibody following Hepatitis B vaccination on Minnesota health care workers. JAMA 1993; 270:2935-9.*
4. Lemon SM, Thomas DL. *Vaccine to prevent viral hepatitis. N Eng J Med 1997; 336:196-204.*
5. Perera P, Perera B, Gamage S. *Seroconversion rate hepatitis B vaccination in healthy young adults and effect of a booster dose. <http://slmaonline.org/cmj/CMJ4701/6.htm>*
6. Mahoney FJ. *Update on diagnosis, management and prevention of Hepatitis B virus infection. Clin Microbiol Rev 1999; 12:351-6.*
7. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. *What level of Hepatitis B antibody is protective? J Infect Dis 1999; 179:489-92.*
8. Louthier J, Rivera P, Villa N, et al. *Hepatitis B vaccination program at a New York city hospital : seroconversion and declination. Am J Infect Control. 1998; 26: 423-7.*
9. Sharifi MR, Ghorieshian SM. *Evaluation of effect of hepatitis B vaccination in HCW in university of shahid Sadooghi, Yazd. Journal of Shahid Sadooghi University 1998; 5(1):10-14.*
10. Pahlavanzadeh H, Montazeri A, Yaaghoobi J, *Evaluation of effect of HBV vaccine in HCW in Tabriz. 1992. <http://www.hbi.dmr.or.ir/hosting/bioterrorism/computerized-books/congereh/congzip.exe.pp1061>*
11. Ayazi F, Darvish Damavandi F, Shafiee M, Alibieghi P. *Evaluation of immunologic response against HBV vaccine in HCW in Tehran <http://www.hbi.dmr.or.ir/hosting/bioterrorism/computerized-books/congerh/congzip.exe.pp1758>*
12. Moosavi Nasab SM, Mokhtari M, Micaeli J, Malekzadeh R. *Evaluation of anti HbsAb titer in Shariati hospital. <http://www.hbi.dmr.or.ir/hosting/bioterrorism/computerized-books/congzip.exe.pp1642>.*
13. David J. Weber, William A Rutala. *Vaccine for Health care workers in: Plotkin AS, Ornstein WA. Vaccine. 4th ed. Saunders 2004:1524-5.*
14. Hadler SC, Francis DP, Maynard JE, et al. *Long term immunogenicity and efficacy of Hepatitis B vaccine in homosexual men. N Eng J Med 1986; 315:209-14*
15. Brodrick A, Jonas MM. *Hepatitis B and D viruses in: Figin, Cherry, Demmler, Kaplan Text book of pediatric infectious disease, WB.Saunders 2004 :1876*
16. Havlichek D, Rosenman K, Simms M, Guss P. *Age-related hepatitis B seroconversion rates in HCWs. Am J Infect Control 1997; 25(5): 418-20.*
17. Koff RS. *Hepatitis vaccines. Infect Dis Clin North Am 2001; 15: 83-95*
18. Koziel MJ, Siddiqui A. *Hepatitis B virus and Hepatitis Delta virus in: Mandell, Douglas and Bennett's principle and practice of infectious disease. 6th ed, Elsevier 2005:1884*